IP Library Granted Patent US 11,820,802
Granted Patent B2
US 11,820,802 · App. 16/328,058 · Granted Nov 21, 2023

Ligand and use thereof

Inventors: Sophia Hober (Stockholm, SE); Sara Kanje (Stockholm, SE); Johan Nilvebrant (Taby, SE)
Assignee: Cytiva BioProcess R&D AB
C07K14/4728C07K1/22C07K14/31C07K2319/20C07K2319/30C07K2319/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,820,802
App. No.
16/328,058
Granted
Nov 21, 2023
Kind
B2
Abstract

The present invention is within the field of protein engineering and purification. The invention relates to a target-binding polypeptide mutant of an IgG binding polypeptide, such as Protein A, Protein G, Protein L or Protein M, comprising a metal binding motif. More closely the invention relates to an Fc binding ligand comprising an engineered protein based on the Protein A derived Z domain, to which a calcium binding EF-loop has been introduced.

Claims (22)

1. A Fc-binding polypeptide mutant of an IgG-binding polypeptide comprising the amino acid sequence selected from SEQ ID NOs: 1-9 (Zmat1-Zmat9),wherein the Fc-binding polypeptide mutant is a mutant of domain Z derived from Staphylococcus Protein A (SpA) domain B and comprises a metal binding motif inserted between helix 2 and 3 of the mutant of domain Z, wherein Fc binding occurs in the presence of a metal ion and wherein the Fc-binding polypeptide mutant optionally comprises the following Z domain mutation: N23T.

2. The Fc-binding polypeptide mutant according to claim 1 , wherein the metal binding motif is calcium binding and the Fc-binding is in the presence of calcium ions.

3. The Fc-binding polypeptide mutant according to claim 1 , comprising a linker before the metal binding motif.

4. The Fc-binding polypeptide mutant according to claim 1 , comprising the amino acid sequence of SEQ ID NO: 8 (Zmat8).

5. The Fc-binding polypeptide mutant according to claim 1 , comprising the following domain Z mutations: F5L, N28K, K35I.

6. A ligand comprising the Fc-binding polypeptide mutant according to claim 1 .

7. The ligand according to claim 6 , comprising the Fc-binding polypeptide mutant comprising the amino acid sequence of SEQ ID NO: 8 (Zmat8).

8. The ligand according to claim 6 , wherein the ligand is a multimer selected from a dimer, trimer, tetramer, pentamer or hexamer.

9. A chromatography matrix comprising the ligand according to claim 6 or multimer thereof.

10. A polypeptide comprising the amino acid sequence selected from SEQ ID Nos:1-9 (Zmat1-Zmat9).

11. The polypeptide of claim 10 , wherein the amino acid sequence is SEQ ID NO:8.

12. A method for purification of target or sample proteins, comprising binding the target or sample proteins to a the ligand according to claim 6 or multimer thereof in the presence of a metal ion; and eluting bound proteins by addition of a metal binding molecule.

13. The method according to claim 12 , wherein the ligand or multimer ligand is immobilized to a solid phase.

14. The method according to claim 12 , wherein the bound proteins are eluted at a pH above 4.5.

15. The method according to claim 14 , where the bound proteins are eluted at pH 5-7.

16. The method according to claim 15 , where the bound proteins are eluted at pH 5.4-5.6.

17. The method according to claim 12 , wherein the target or sample proteins are antibodies or portions thereof.

18. The method according to claim 17 , wherein the target or sample proteins are IgG.

19. The method according to claim 17 , wherein the target or sample proteins are Fc-fusion proteins.

20. The method according to claim 12 , wherein the elution with metal binding molecule is with a chelating agent.

21. A nucleic acid or vector encoding a polypeptide comprising the amino acid sequence selected from SEQ ID NOs: 1-9.

22. An expression vector comprising the nucleic acid or vector of claim 21 .

Assignments (2)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2019
From: HOBER, SOPHIA; KANJE, SARA; NILVEBRANT, JOHAN
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 048426/0063 →
Priority Claims (2)
GB 1615254 · Sep 8, 2016 · national
GB 1705960 · Apr 13, 2017 · national
Continuity (1)
Related Publication 20190218265A1 · Jul 18, 2019